Dry eye syndrome: Neuroptis successfully completes the pre-clinical phase for ML7

Neuroptis is looking to establish industrial and financial partnerships to commence human trials

Trophos announces final patient completion of pivotal phase three efficacy study of olesoxime in Amyotrophic Lateral Sclerosis

Medicago announces an extension of its agreement with Genopole biopark

New strategies for cancer drug development urgently needed

Era of personalized oncology required new thinking from governments, companies and clinicians, say experts at ESMO symposium

ORVACS Phase II clinical study attacks the viral reservoir of HIV patients

Trophos initiates pivotal efficacy study of olesoxime in Spinal Muscular Atrophy

Neovacs achieves key clinical milestones

Endotis Pharma presents Phase I clinical trial results for a first-in-class synthetic parenteral neutralizable anticoagulant

EyeTechCare raises EUR 7.5 million in a second funding round and speeds up its development

Servier and Galapagos initiate strategic alliance in osteoarthritis

Axol Bioscience acquires Phenocell to advance human disease models

Acquisition expands Axol’s iPSC-derived cell models and service offering to include ophthalmology and dermatology

Amolyt Pharma completes acquisition by AstraZeneca

AstraZeneca has acquired all of Amolyt Pharma’s outstanding shares for up to $1.05 billion

Danone, start-up DMC, Michelin and Crédit Agricole Centre France join forces to create a cutting-edge biotechnology platform

Using precision fermentation to produce sustainable, bio-based materials and ingredients

Evotec, Inserm, Lille University Hospital and Inserm Transfert enter collaboration

Identification of novel therapeutic targets in obesity and metabolic diseases

En Carta Diagnostics secures €1.5M to advance diagnostic kit platform for early Lyme disease detection

Groundbreaking patented molecular diagnostic kit poised to provide game-changing autonomous Lyme detection in minutes

Investors focus on therapies for untreatable serious diseases

Start-up 4P-Pharma secures another million-euro investment

CARBIOS celebrates the groundbreaking of its PET biorecycling plant

CARBIOS’ first plant is also a world first using revolutionary enzymatic depolymerization technology

SeaBeLife awarded over €1.5 million in i-Nov innovation competition

Funding for company’s SeaBeEYE project will be used to develop new therapeutic approach for geographic atrophy – advanced form of dry AMD

BASSETTI GROUP acquires the German software provider MAQSIMA

Start-up aims to harness the natural powers of cancer survivors to cure this life-threatening disease

Cure51 raises a €15 million seed round

Amolyt Pharma completes acquisition by AstraZeneca

AstraZeneca has acquired all of Amolyt Pharma’s outstanding shares for up to $1.05 billion

Evotec and Pfizer collaborate to advance drug discovery in France

Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases

Investors focus on therapies for untreatable serious diseases

Start-up 4P-Pharma secures another million-euro investment

SeaBeLife awarded over €1.5 million in i-Nov innovation competition

Funding for company’s SeaBeEYE project will be used to develop new therapeutic approach for geographic atrophy – advanced form of dry AMD

Start-up Dynamic42 and Biopredic join for strategic Marketing agreement

New partnership to promote pioneering in vitro systems in drug development

ANTABIO Raises €25 Million in Series B Financing

The financing will be used to support the clinical development of a next generation antibacterial combination

Cellectis enters into strategic collaboration and investment agreement with AstraZeneca

Cellectis to receive up to $245M in cash, with potential for additional milestones, plus tiered royalties

A new molecule to target and eliminate cancer cells using light

This new photosensitizer has proved much more effective than those used in current treatments.

Sartorius acquires French provider of innovative upstream technologies for cell and gene therapies

Agreed purchase price of approximately 2.4 billion euros

Merck Boosts Commercial Capacity in France

Merck has opened a commercial facility for its new Millipore® CTDMO Services offering at the company’s site in Martillac, France